Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib

被引：6
|
作者：
Piper-Vallillo, Andrew J. [1 ,2 ,3 ]
Sequist, Lecia V. [2 ,3 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Massachusetts Gen Hosp, 55 Fruit St,BHX-1-125, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
JACC: CARDIOONCOLOGY | 2019年 / 1卷 / 02期
关键词：
cardiotoxicity; EGFR; NSCLC; osimertinib;
D O I：
10.1016/j.jaccao.2019.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 181
页数：3
相关论文
共 50 条
  • [1] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [2] Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Mehta, Anurag
    Jain, Parveen
    Bansal, Abhishek
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (01):
  • [3] Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer
    Li, Wendong
    Rotter-Maskowitz, Aviva
    Zhang, Keqiang
    Massarelli, Erminia
    Potempa, Jan
    Straussman, Ravid
    Raz, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Piper-Vallillo, Andrew J.
    Sequist, Lecia, V
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2926 - +
  • [5] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
    Gautschi, Oliver
    Menon, Roopika
    Bertrand, Miriam
    Murer, Christian
    Diebold, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
  • [6] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [7] Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
    Adua, Sally J.
    Arnal-Estape, Anna
    Zhao, Minghui
    Qi, Bowen
    Liu, Zongzhi Z.
    Kravitz, Carolyn
    Hulme, Heather
    Strittmatter, Nicole
    Lopez-Giraldez, Francesc
    Chande, Sampada
    Albert, Alexandra E.
    Melnick, Mary-Ann
    Hu, Bomiao
    Politi, Katerina
    Chiang, Veronica
    Colclough, Nicola
    Goodwin, Richard J. A.
    Cross, Darren
    Smith, Paul
    Nguyen, Don X.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [8] Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
    Sally J. Adua
    Anna Arnal-Estapé
    Minghui Zhao
    Bowen Qi
    Zongzhi Z. Liu
    Carolyn Kravitz
    Heather Hulme
    Nicole Strittmatter
    Francesc López-Giráldez
    Sampada Chande
    Alexandra E. Albert
    Mary-Ann Melnick
    Bomiao Hu
    Katerina Politi
    Veronica Chiang
    Nicola Colclough
    Richard J. A. Goodwin
    Darren Cross
    Paul Smith
    Don X. Nguyen
    Nature Communications, 13
  • [9] A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
    Takano, Natsuki
    Seike, Masahiro
    Sugano, Teppei
    Matsuda, Kuniko
    Hisakane, Kakeru
    Yoshikawa, Akiko
    Nakamichi, Shinji
    Noro, Rintaro
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2022, 42 (02) : 709 - 722
  • [10] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
12345